FUJIFILM Pharmaceuticals USA
  • Home
  • Investigational Drug Development
  • Contract Services
    • LNPs and Liposomes
    • Nano-dispersion Technologies
  • Resources
    • Drug Delivery Formulation
    • Peer-Reviewed Publications and Conference Presentation
    • Oncology
    • Alzheimer’s Disease
  • News
  • About Us
  • Contact Us
Select Page

Fujifilm Takes Action and Coordinates Efforts to Support Healthcare Needs for Clinical Staff Engaged in Phase II Clinical Trials

At Fujifilm, our dedication to science and innovation has never been more important than it is today. We are collaborating across the globe and working together and finding ways to fight COVID-19 by leveraging our talents, experience and resources.

But perhaps nothing is more inspiring than the way several FUJIFILM Group companies came together recently to provide hundreds of personal protective equipment (PPE) units —all in a single day.

The goal was to get much-needed PPE to the physicians and healthcare workers engaged in the phase II clinical trials of Avigan (generic name: favipiravir) sponsored by FUJIFILM Pharmaceuticals U.S.A., Inc. Yet hospitals around the country face the same challenge: there were limited supplies of PPE which are critical to protect healthcare professionals while caring for patients.

Without PPE our Avigan trials could have faced a delay, but the Fujifilm community refused to let that get in the way. In a matter of just a few hours from when Mikihiko Kato, President of FUJIFILM Pharmaceuticals U.S.A., Inc., put out the call for more PPE, Fujifilm teams quickly mobilized to gather necessary PPE and deliver it to the trial sites in Massachusetts.
Team members at FUJIFILM Holdings America Corporation, FUJIFILM North America Corporation, FUJIFILM Recording Media U.S.A., Inc., FUJIFILM Dimatix Inc., and FUJIFILM Irvine Scientific Inc. pooled resources and delivered the necessary N95 masks, face shields, gloves, booties, hair nets and Tyvek Suites, in under 24 hours in order to kick off the trials on schedule.

“A key marker of our people at Fujifilm is the ability to innovate, perform and solve challenges in times of crisis. It is in our DNA,” said Mikihiko Kato, President, FUJIFILM Pharmaceuticals U.S.A., Inc. “Today and in the future, our collaboration is helping to improve patient lives around the world. I am proud of the Fujifilm family.”
Amid all the strife that surrounds us, the stories of collaboration and service are truly powerful. They remind us that we’re in this together.

###

PRIVACY POLICY      TERMS OF USE

TRUSTe
  • Follow
© 2022 FUJIFILM Pharmaceuticals U.S.A., Inc.
Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.
By continuing to use this site you are giving us your consent to do this. For more information you can read our Privacy Policy. Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Tumor targeting by liposomes

Liposomes provide a delivery system that carries the required amount of a drug to the specific area of the body. Because of that, one potential application for liposomes is anti-cancer formulations. Studies have suggested that liposomes are delivered to tumors through the enhanced permeability and retention (EPR) effect1. As a passive targeting mechanism, EPR effect allows the accumulation of drugs within the tumor tissue thanks to immature, highly permeable vasculature and ineffective lymphatic system that allow efficient extravasation of such macromolecules.

1 Yingchoncharoen P., Kalinowski D.S., Richardson D.R. 2016. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev. 68(3):701-87.

Promising vehicle for nucleic acids

Nucleic acids (mRNA, siRNA, DNA aptamers, etc.) are the new frontiers of drug discovery. However, the industry has faced technological challenges in commercializing nucleic acid medicines due to their poor pharmacological stability. Lipid nanoparticle has been studied for a decade as a potential solution to this problem, which recently is coming to fruition in some clinical applications, such as mRNA-based COVID-19 vaccines.